| |
Trials
|
All
|
ACT
|
AHT
|
APT
|
CEA
|
GL
|
HRT
|
Statins
|
Vitamins
|
P
|
|---|
|
All
| | |
N = 8
|
N = 8
|
N = 7
|
N = 3
|
N = 1
|
N = 2
|
N = 4
|
N = 2
| |
|
Primary (%)
|
15
| |
4 (36.7%)
|
6 (40.0%)
|
0
|
1 (6.7%)
|
1 (6.7%)
|
2 (13.3%)
|
1 (6.7%)
|
0
| |
|
Secondary (%)
|
20
| |
4 (20.0%)
|
2 (10.0%)
|
7 (35.0%)
|
2 (10.0%)
|
0
|
0
|
3 (15.0%)
|
2 (10.0%)
| |
|
Baseline
|
|
Number
|
35
|
254,223
|
54,713
|
81,058
|
39,714
|
5074
|
10,251
|
27,347
|
24,222
|
11,844
| |
|
Age
|
35
|
65.1 (30.5)
|
69.0 (11.7)
|
64.6 (51.9)
|
66.0 (9.6)
|
66.6 (8.2)
|
62.8 (6.6)
|
63.4 (7.2)
|
59.3 (8.1)
|
63.7 (12.1)
|
< 0.0001
|
|
Sex, Female (%)
|
35
|
117,222 (46.1%)
|
21,063 (38.5%)
|
39,213 (48.4%)
|
14,697 (37.0%)
|
2711 (53.4%)
|
3952 (38.6%)
|
27,347 (100%)
|
3916 (16.2%)
|
4323 (36.5%)
|
< 0.0001†
|
|
Medical History (%)
|
|
Diabetes
|
34
|
51,131 (20.1%)
|
7030 (12.9%)
|
17,143 (21.2%)
|
8897 (22.4%)
|
1135 (22.4%)
|
10,251 (100%)
|
1980 (7.2%)
|
1725 (7.1%)
|
2970 (25.3%)
|
< 0.0001‡
|
|
Hypertension
|
32
|
153,427 (69.6%)
|
22,771 (67.0%)
|
76,550 (94.5%)
|
25,871 (65.2%)
|
3212 (63.3%)
|
–
|
8433 (34.0%)
|
8141 (33.6%)
|
8449 (72.0%)
|
< 0.0001
|
|
Hyperlipidaemia
|
17
|
27,627 (29.8%)
|
96 (9.6%)
|
1019 (15.4%)
|
14,757 (37.3%)
|
1291 (37.8%)
|
–
|
3366 (13.7%)
|
4444 (40.2%)
|
2654 (41.7%)
|
< 0.0001
|
|
IHD
|
12
|
27,850 (30.6%)
|
–
|
8813 (24.0%)
|
6724 (20.7%)
|
1970 (38.8%)
|
–
|
–
|
9014 (100%)
|
1329 (17.0%)
|
< 0.0001¥
|
|
Stroke
|
28
|
21,645 (12.6%)
|
3403 (9.6%)
|
5375 (13.9%)
|
8707 (23.9%)
|
717 (21.0%)
|
630 (6.1%)
|
306 (1.1%)
|
369 (4.1%)
|
2138 (18.2%)
|
< 0.0001
|
|
MI
|
25
|
22,069 (13.6%)
|
5073 (14.4%)
|
704 (2.1%)
|
2720 (7.7%)
|
640 (18.8%)
|
1590 (15.5%)
|
634 (2.3%)
|
10,708 (60.8%)
|
–
|
< 0.0001
|
|
Smoking, Current
|
31
|
48,441 (20.9%)
|
7030 (21.0%)
|
17,515 (21.9%)
|
10,211 (25.8%)
|
1471 (29.0%)
|
1247 (12.2%)
|
2831 (10.5%)
|
3496 (14.4%)
|
4640 (39.5%)
|
< 0.0001
|
|
Alcohol
|
12
|
27,897 (41.3%)
|
6373 (34.2%)
|
4754 (48.0%)
|
10,984 (40.5%)
|
561 (33.8%)
|
–
|
–
|
3098 (46.9%)
|
2127 (59.4%)
|
< 0.0001
|
|
SBP
|
31
|
145.8 (23.1)
|
143.5 (27.1)
|
155.2 (19.8)
|
147.4 (20.2)
|
146.1 (19.3)
|
–
|
128.7 (17.6)
|
136.5 (18.8)
|
141.5 (20.9)
|
< 0.0001
|
|
DBP
|
30
|
83.3 (12.0)
|
79.5 (12.8)
|
87.7 (11.1)
|
84.9 (11.7)
|
80.1 (10.0)
|
–
|
76.0 (9.2)
|
80.3 (10.4)
|
81.6 (12.1)
|
< 0.0001
|
|
HR
|
14
|
73.1 (13.7)
|
75.1 (15.8)
|
77.5 (11.6)
|
73.2 (12.4)
|
73.1 (10.6)
|
–
|
–
|
67.8 (11.1)
|
–
|
< 0.0001
|
|
Secondary
|
|
Qualifying event (%)
|
|
Stroke
|
19
|
71,178 (66.4%)
|
19,779 (60.9%)
|
5632 (85.2%)
|
34,071 (85.8%)
|
1571 (46.0%)
|
–
|
–
|
–
|
10,125 (86.1%)
|
< 0.0001
|
|
MI
|
19
|
25,528 (22.9%)
|
12,090 (37.2%)
|
–
|
–
|
–
|
–
|
–
|
1348 (76.3%)
|
–
|
< 0.0001
|
|
TIA
|
19
|
9979 (9.3%)
|
347 (1.1%)
|
974 (14.7%)
|
5497 (13.8%)
|
1759 (51.6%)
|
–
|
–
|
–
|
1402 (11.9%)
|
< 0.0001
|
|
OTR
|
18
|
91.2 (246.2)
|
3.2 (12.9)
|
418.0 (439.6)
|
31.0 (163.5)
|
47.9 (43.6)
|
–
|
–
|
507.4 (317.0)
|
60.2 (178.0)
|
< 0.0001
|
- ACT: anticoagulants; AHT: antihypertensives; APT: antiplatelets; CEA: carotid endarterectomy; DBP: diastolic blood pressure; GL: glucose lowering; HRT: hormone replacement therapy; IHD: ischaemic heart disease; MI: myocardial infarction; HR: heart rate; OTR: onset to randomisation; SBP: systolic blood pressure; TIA: transient ischaemic attack. Percentages (%) are out of the total number of participants with available data. Comparisons by Chi-Square test and ANOVA. †Excluding HRT group. ‡Excluding GL group. ¥Excluding Statins group
